CDK9 PROTACs

Cutting edge anti-cancer approach targets CDK9

  • Targeted degradation of CDK9
  • Nanomolar potency
  • Sensitizes pancreatic cancer cells to Bcl2 inhibitor

 
Licensing Manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166
 

SKU: 619 Category: Tags: , ,

Description

Cutting edge anti-cancer approach targets CDK9

University of Nebraska Medical Center researchers created an inhibitor that targets cyclin-dependent kinase 9 (CDK9), a protein that regulates several oncogenes, which are often responsible for tumor growth.
 
This new CDK9 inhibitor is a PROTAC, or Proteolysis targeting chimera, which is a class of inhibitors that harness the body’s own protein degradation machinery to eliminate cancer-related proteins.
 
This new CDK9 PROTAC degrades CDK9 at nanomolar concentrations without degrading other CDKs or CDK9-binding partners in pancreatic cancer cells.
 
The CDK9 PROTAC can also sensitize pancreatic cancer cells to an FDA approved Bcl2 inhibitor Venetoclax, a cancer treatment patients commonly develop resistance to.
 
To discuss licensing opportunities contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.
 

Additional information

Technology Manager

Matt Boehm